Porphyria cutanea tarda

Australasian Journal of Dermatology

Volumn 41, Issue 4, 2000, Pages 197-208

  Bleasel, Narelle R ^a   Varigos, George A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Haemochromatosis; Hepatitis C virus; Hepatoerythropoietic porphyria; Iron; Uroporphyrinogen decarboxylase

Indexed keywords

CHLOROQUINE; FERRITIN; HEME; HYDROXYCHLOROQUINE; PORPHYRIN; UROPORPHYRINOGEN DECARBOXYLASE;

CHROMOSOME 1P; CLINICAL EXAMINATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; HEME SYNTHESIS; HISTOPATHOLOGY; HUMAN; PATHOPHYSIOLOGY; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; REVIEW; RISK FACTOR; SKIN BIOPSY;

AUSTRALIA; FEMALE; HUMANS; MALE; PORPHYRIA CUTANEA TARDA; PROGNOSIS; RISK FACTORS;

EID: 0033678778     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2000.00437.x     Document Type: Review

References (152)

1. Porphyria cutanea tarda
2. Porphyria cutanea tarda of the toxic and sporadic varieties
3. Porphyria cutanea tarda. Diagnosis and management
4. Pathophysiology of cutaneous lesions in porphyrias
5. Cutaneous deposition diseases
6. Uroporphyrinogen decarboxylase
7. Assignment of the gene for uroporphyrinogen decarboxylase to human chromosome I by somatic cell hybridization and specific enzyme immunoassay
8. Molecular cloning and nucleotide sequence of a complete human uroporphyrinogen decarboxylase cDNA
9. Genetics and pathogenesis of human uroporphyrinogen decarboxylase defects
10. Familial and sporadic porphyria cutanea: Two different diseases
11. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda
12. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda
13. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda
14. Decreased hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda
15. Porphyria cutanea tarda in three generations of a single family
16. Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase
17. Erythrocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda
18. Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria
19. Uroporphyrinogen decarboxylase: A splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda
20. Familial porphyria cutanea tarda with normal erythrocytic urodecarboxylase: An exception to the rule?
21. Heterogeneity of familial porphyria cutanea tarda
22. Erythrocyte uroporphyrinogen decarboxylase activity in porphyria cutanea tarda: A study of 40 consecutive patients
23. Hepatoerythropoietic porphyria: A new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda?
24. Hepatoerythropoietic porphyria: A variant of childhood-onset porphyria cutanea tarda. Porphyrin profiles and enzymatic studies of two cases in a family
25. A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: Biochemical and genetic studies on Spanish patients
26. Uroporphyrinogen decarboxylase: Complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria
27. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria
28. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria
29. Cutaneous porphyria in Turkey
30. Aquired toxic porphyria cutanea tarda due to hexachlorobenzene
31. Porphyria turcica due to hexachlorobenzene: A 20-30 year follow-up study on 204 patients
32. Industrially acquired porphyria
33. Porphyria cutanea tarda: A multifactorial disease
34. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients
35. Effect of ethanol on liver delta aminolaevulinate synthase activity and urinary porphyrin excretion in symptomatic porphyria
36. Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: Possible explanation for iron overload
37. Is hepatitis C virus infection a trigger of porphyria cutanea tarda?
38. The pathology of the liver in porphyria cutanea tarda
39. Estrogen-induced porphyria cutanea tarda. Report of three cases
40. Manifestation of familial porphyria cutanea tarda after childbirth
41. The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: The role of iron
42. Hepatitis B virus infection in porphyria cutanea tarda
43. Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases
44. Iron and hepatic uroporphyrin synthesis. Relation in porphyria cutanea tarda
45. The effect of replenishment of iron stores after phlebotomy therapy in porphyria cutanea tarda
46. Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells
47. Dual mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron: Its potential role in the genesis of porphyria cutanea tarda
48. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda
49. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda
50. Porphyria cutanea tarda and antibodies to hepatitis C virus
51. Porphyria cutanea tarda and hepatitis C viral infection. A clinical and virologic study
52. Porphyria cutanea tarda and hepatitis C and B viruses infection: A retrospective study
53. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association
54. Porphyria cutanea tarda and hepatitis G and C virus infection
55. High prevalence of hepatitis C virus infection in patients with porphyria cutanea tarda in Poland
56. Porphyria cutanea tarda and hepatitis C virus infection
57. Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature
58. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America
59. Hepatitis C virus infection in patients with porphyria cutanea tarda evaluated in New York, NY
60. Porphyria cutanea tarda and hepatitis C
61. Hepatitis C virus infection and porphyria cutanea tarda in Australasia
62. HCV infection in porphyria cutanea tarda
63. Hepatocellular carcinoma in porphyria cutanea tarda: Frequency and factors related to its occurrence
64. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany
65. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda
66. Inherited disorders of iron metabolism
67. Porphyrin metabolism in hepatitis C infection
68. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. A study of 177 patients
69. Type of impaired porphyrin metabolism caused by hepatitis C virus is not porphyria cutanea tarda but chronic hepatic porphyria
70. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection
71. Hepatitis C virus in dermatology. A review
72. A multifaceted disease. Review of extrahepatic manifestations
73. Porphyrin abnormalities in acquired immunodeficiency syndrome
74. Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection
75. Porphyria cutanea tarda and HIV/AIDS. A review of pathogenesis, clinical manifestations and management
76. Hepatic manifestations of porphyria cutanea tarda in a patient with AIDS
77. Porphyria cutanea tarda associated with human immunodeficiency virus infection. A study of four cases and review of the literature
78. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome
79. Human immunodeficiency virus infection and porphyria cutanea tarda: Coexistence of risk factors or causative association?
80. Porphyria cutanea tarda as initial presentation of the acquired immunodeficiency syndrome in two patients
81. Porphyria cutanea tarda and human immunodeficiency virus infection
82. Isolation of human imnnmodeficiency virus type 1 in cutaneous blister fluid
83. Hepatitis C vires and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda
84. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
85. A population-based study of the clinical expression of the hemochromatosis gene
86. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda
87. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload
88. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda
89. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda
90. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients
91. Cutaneous abnormalities and metabolic disturbance of porphyrins in patients on maintenance haemodialysis
92. Porphyria cutanea tarda associated with chronic renal disease and hemodialysis
93. Porphyria cutanea tardia in two patients treated with hemodialysis for chronic renal failure
94. Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients
95. Discoid lupus erythematosus and porphyria cutanea tarda
96. Lupus erythematosus and porphyria. Coexistence in seven patients
97. Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients
98. Treatment of porphyria cutanea tarda by phlebotomy
99. Porphyria cutanea tarda and hematologic malignancy: A report of 4 cases
100. Porphyria cutanea tarda and chronic lymphoid leukemia
101. Porphyria cutanea tarda resulting from primary hepatocellular carcinoma
102. Association of porphyria cutanea tarda and primary liver cancer: Report of ten cases
103. Histologic and immunofluorescence study of cutaneous porphyrias
104. Caterpillar bodies: Distinctive, basement membrane-containing structures in blisters of porphyria
105. Caterpillar bodies of porphyria cutanea tarda ultrastructurally represent a unique arrangement of colloid and basement membrane bodies
106. Increased mast cell numbers in the sclerotic skin of porphyria cutanea tarda
107. Histopathology of the skin in acquired and hereditary porphyria cutanea tarda
108. Liver involvement in porphyria
109. Uroporphyrinogen decarboxylase deficiencies: Porphyria cutanea tarda and related conditions
110. The treatment of porphyria cutanea tarda by venesection
111. Porphyrias and porphyrins
112. Hypertrichosis as the presenting feature of porphyria cutanea tarda
113. Scarring alopecia and sclerodermatous changes of the scalp in a patient with hepatitis C infection
114. Generalized morphoea secondary to porphyria cutanea tarda
115. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors
116. The diagnosis and follow up of porphyria
117. Correlation of serum and urinary porphyrin levels in porphyria cutanea tarda
118. Clinical laboratory methods for diagnosis of the porphyrias
119. The effect of certain anaesthetic agents on the activity of rat hepatic δ-aminolaevulinate synthase
120. The pattern of porphyrin isomer accumulation and excretion in symptomatic porphyria
121. Effective control of patients with porphyria cutanea tarda by measuring plasma uroporphyrin
122. Management of patients with porphyria cutanea tarda
123. Recovery from porphyria cutanea tarda with no specific therapy other than avoidance of hepatic toxins
124. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection
125. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda
126. Porphyria cutanea tarda A study of the effect of phlebotomy N Engl
127. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda
128. Agents affecting porphyrin formation and secretion: Implications for porphyria cutanea treatment
129. The therapeutic effect of chloroquine. Hepatic recovery in porphyria cutanea tarda
130. Toxic effect of chloroquine on porphyria hepatica
131. Effects of chloroquine on patients with cutaneous porphyria of the 'symptomatic' type
132. Effect of chloroquine on hepatic uroporphyrin metabolism in patients with porphyria cutanea tarda
133. Treatment of porphyria cutanea tarda with chloroquine
134. Porphyria cutanea tarda. Remission following chloroquine administration without adverse effects
135. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda
136. Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria
137. Very low-dose chloroquine treatment for porphyria cutanea tarda
138. Treatment of porphyria cutanea tarda with chloroquine and phlebotomy
139. Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy
140. Choice of therapy in porphyria cutanea tarda
141. Hydroxychloroquine treatment of porphyria cutanea tarda
142. High-dose hydroxychloroquine treatment of porphyria cutanea tarda
143. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda
144. Childhood-onset porphyria cutanea tarda: Successful therapy with low-dose hydroxychloroquine (Plaquenil)
145. Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine
146. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis
147. Porphyria cutanea tarda in a dialyzed patient with hepatitis C virus infection: Dramatic efficacy of small repeated phlebotomies
148. Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietin
149. Treatment of porphyria cutanea tarda with oral thalidomide
150. Small, plasmapheresis in the management of porphyria cutanea tarda
151. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C
152. Porphyria cutanea tarda in a human immunodeficiency virus-infected patient: Treatment with N-acetyl-cysteine